Genetically modified bacteria enlisted in fight against disease
Open accessThe claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Bacteroides ovatus transferred modified genes to resident bacteria and acquired genes enabling survival in the mice gut within 72 hours, despite a biological kill switch.
“Simon Carding’s team found that Bacteroides ovatus transferred the modified genes to resident bacteria and acquired genes enabling survival in the mice gut within 72 hours, despite the biological “kill switch” that was built to prevent the microbes from surviving in vitro.18,19”
From Gut microbiota drives structural variation of exogenous probiotics to enhance colonization (2025) · cites this paper as [18]
In “Bacteria deliver gene therapies,” the paper reports that B. ovatus passed its modified gene to other gut microbes within 72 hours and acquired genes that let it live without a molecule on which the engineered strain depended. It does not say those genes enabled survival in the mice’s gut specifically; it describes kill switches as intended to prevent survival outside the body, not specifically in vitro. (LLM, conf=0.86)
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Cites
Gosmann, C., Anahtar, M. N., Handley, S. A., Farcasanu, M., Abu-Ali, G., Bowman, B. A., Padavattan, N., Desai, C., Droit, L., Moodley, A., et al. (2017) · Immunity · doi:10.1016/j.immuni.2016.12.013 · Cited by 696 · see citing works
Hwang, I. Y., Koh, E., Wong, A., March, J. C., Bentley, W. E., Lee, Y. S., & Chang, M. W. (2017) · Nature Communications · doi:10.1038/ncomms15028 · Cited by 472 · see citing works
Use of genetically modified bacteria for drug delivery in humans: Revisiting the safety aspect
Wegmann, U., Carvalho, A. L., Stocks, M., & Carding, S. R. (2017) · Scientific Reports · doi:10.1038/s41598-017-02591-6 · Cited by 53 · see citing works
Flagged first, then by citations
Research works printed but not linked: 2
- Hwang, I. Y. et al. Nature Commun. 8, 15028 (2017).
- Wegmann, U., Carvalho, A. L., Stocks, M. & Carding, S. R. Sci. Rep. 7, 2294 (2017). The Escherichia coli bacteria is being developed as a vehicle for gene therapy in people.
Cited by
Sorted by citations
Salminen, S., Collado, M. C., Endo, A., Hill, C., Lebeer, S., Quigley, E. M. M., Sanders, M. E., Shamir, R., Swann, J. R., Szajewska, H., et al. (2021) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-021-00440-6 · Cited by 2,488 · see citing works
Swanson, K. S., Gibson, G. R., Hutkins, R., Reimer, R. A., Reid, G., Verbeke, K., Scott, K. P., Holscher, H. D., Azad, M. B., Delzenne, N. M., et al. (2020) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-020-0344-2 · Cited by 2,196 · see citing works
Gut microbiota drives structural variation of exogenous probiotics to enhance colonization
Jiang, S., Huang, S., Zhang, Z., Ma, W., Han, Z., Song, Y., Huo, D., Cui, W., & Zhang, J. (2025) · Gut Microbes · doi:10.1080/19490976.2025.2503371 · Cited by 15 · see citing works
“18,19 (4) The complex and dynamic interactions between probiotic bacteria and the unique composition of an individual’s gut microbiome remain a major challenge.”
- Authors
- Reardon, S.
- Corresponding author
- Reardon, Sara
- Venue
- Nature
- Published
- 2018-06-21
- Volume
- 558
- Issue
- 7711
- Pages
- 497-498
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- OpenAlex
- W2808745159
- Cited by
- 19
- References
- 3
- Citations by year
- 2026: 1 · 2025: 3 · 2024: 3 · 2022: 2 · 2021: 3 · 2020: 3 · 2019: 4
- Type
- other
- Language
- en
- Open access
- bronze
- doi.org
- Licence
- Locations
- Nature (publishedVersion)
- PubMed (publishedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Biotechnology › Cancer Research and Treatments
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › CRISPR and Genetic Engineering
- Physical Sciences › Environmental Science › Ecology › Bacteriophages and microbial interactions
- Keywords
- engineered bacteria, engineered microorganisms, Escherichia coli, human trials, disease treatment, microbial therapeutics
- MeSH terms
- Animals, Bacteria, Bacteroides, Biological Therapy, Clinical Trials as Topic, Colitis, Escherichia coli, Humans, Lactobacillus, Phenylalanine, Phenylketonurias, Lactococcus lactis, HIV Infections, Gene Transfer, Horizontal, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
